BM-573 is an orally active dual thromboxane A2 (TXA2) modulator with an IC50 of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA2 analogues). BM-573 completely blocks the generation of TXB2 (the stable metabolite of TXA2) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED50 = 4.2 µM), but has no effect on contractions caused by PGE2, PGF2alpha, or PGI2. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock[1][2].
Molekulargewicht:
406.46
CAS Nummer:
[284464-83-1]
Formel:
C18H22N4O5S
Target-Kategorie:
Prostaglandin Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
